These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10052561)

  • 21. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
    Fuchs PC; Barry AL; Brown SD
    J Chemother; 1997 Dec; 9(6):391-3. PubMed ID: 9491837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
    Bonfiglio G
    Chemotherapy; 2001; 47(4):239-42. PubMed ID: 11399859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci.
    Noviello S; Ianniello F; Esposito S
    J Antimicrob Chemother; 2001 Aug; 48(2):283-6. PubMed ID: 11481302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
    West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
    Kitzis MD; Goldstein FW; Miegi M; Acar JF
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
    Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
    J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.
    Wexler HM; Molitoris E; Molitoris D; Finegold SM
    Antimicrob Agents Chemother; 1998 Apr; 42(4):984-6. PubMed ID: 9559829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
    Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp.
    von Eiff C; Herrmann M; Peters G
    Antimicrob Agents Chemother; 1995 Jan; 39(1):268-70. PubMed ID: 7695321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bacteremia caused by Stomatococcus mucilaginosus in a neutropenic patient].
    Saavedra JM; Rodríguez JN; Vega D; Pascual L; Fernández-Jurado A; Prados D
    Enferm Infecc Microbiol Clin; 1999 Jan; 17(1):42-3. PubMed ID: 10069114
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.